Multimodal Biomarkers for Diagnosis and Prognosis in CAA
A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 240 participants.
Also called NCT03969732
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose diagnostic
- Phase
- Phase 3
- Enrolled
- 240 participants
- Registry
-
NCT03969732
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Taiwan
- Registry status
- Unknown status
Technical summary
Registry record NCT03969732. Allocation not applicable; no masking; primary purpose diagnostic. Start 2018-09-27 (actual); primary completion 2022-07-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Multimodal Biomarkers for Diagnosis and Prognosis in CAA
- Acronym
- CAA
- Condition
- Cerebral Amyloid Angiopathy
- Condition
- Intracranial Hemorrhages
- Condition
- Alzheimer Disease
- Intervention (Drug)
- 1. amyloid PET;2. T807 PET
- Lead sponsor
- National Taiwan University Hospital
Record details
- Record id
cardio:ct-nct03969732- Content hash
7bb9eb3380995673e6fdf737584d2c57215f5dcb9151622ee9b9eccd5020f4e6